GW Pharmaceuticals’ Epidyolex has become the first ever plant-derived cannabinoid medicine to be authorized by the Europe Commission for use across the EU.
The product, approved for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), is...








